Current Practices and Challenges in the Diagnosis and Management of PKU in Latin America: A Multicenter Survey

This study aimed to describe the current practices in the diagnosis and dietary management of phenylketonuria (PKU) in Latin America, as well as the main barriers to treatment. We developed a 44-item online survey aimed at health professionals. After a pilot test, the final version was sent to 25 practitioners working with inborn errors of metabolism (IEM) in 14 countries. Our results include 22 centers in 13 countries. Most countries (12/13) screened newborns for PKU. Phenylalanine (Phe) targets at different ages were very heterogeneous among centers, with greater consistency at the 0–1 year age group (14/22 sought 120–240 µmol/L) and the lowest at >12 years (10 targets reported). Most countries had only unflavored powdered amino acid substitutes (10/13) and did not have low-protein foods (8/13). Only 3/13 countries had regional databases of the Phe content of foods, and only 4/22 centers had nutrient analysis software. The perceived obstacles to treatment were: low purchasing power (62%), limited/insufficient availability of low-protein foods (60%), poor adherence, and lack of technical resources to manage the diet (50% each). We observed a heterogeneous scenario in the dietary management of PKU, and most countries experienced a lack of dietary resources for both patients and health professionals.

[1]  G. Borrajo Newborn screening in Latin America: A brief overview of the state of the art , 2021, American journal of medical genetics. Part C, Seminars in medical genetics.

[2]  M. D. de Castro,et al.  Bone Status in Patients with Phenylketonuria: A Systematic Review , 2020, Nutrients.

[3]  L. Prosser,et al.  The financial and time burden associated with phenylketonuria treatment in the United States , 2019, Molecular genetics and metabolism reports.

[4]  M. Walterfang,et al.  Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments , 2019, Front. Psychiatry.

[5]  A. Macdonald,et al.  Living with Phenylketonuria: Lessons from the PKU community , 2018, Molecular genetics and metabolism reports.

[6]  A. Eldali,et al.  The effects of low protein products availability on growth parameters and metabolic control in selected amino acid metabolism disorders patients , 2018, International journal of pediatrics & adolescent medicine.

[7]  Natalia García Restrepo,et al.  Deficiencia de fenilalanina hidroxilasa : espectro clínico y estado actual del diagnóstico en Colombia. , 2018, Biosalud.

[8]  M. Ribeiro,et al.  Quality of life and adherence to treatment in early-treated Brazilian phenylketonuria pediatric patients , 2017, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[9]  N. Blau,et al.  The complete European guidelines on phenylketonuria: diagnosis and treatment , 2017, Orphanet Journal of Rare Diseases.

[10]  F. Rohr,et al.  Multiclinic Observations on the Simplified Diet in PKU , 2017, Journal of nutrition and metabolism.

[11]  G. Castro,et al.  Chilean Nutrition Management Protocol for Patients With Phenylketonuria , 2017 .

[12]  G. Borrajo Newborn Screening for Phenylketonuria: Latin American Consensus Guidelines , 2016 .

[13]  K. Moseley,et al.  Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach. , 2016, Molecular genetics and metabolism.

[14]  A. Macdonald,et al.  Protein substitutes for phenylketonuria in Europe: access and nutritional composition , 2016, European Journal of Clinical Nutrition.

[15]  J. Loeber,et al.  Current status of newborn screening worldwide: 2015. , 2015, Seminars in perinatology.

[16]  R. Atun,et al.  Health-system reform and universal health coverage in Latin America , 2015, The Lancet.

[17]  K. Gerasimidis,et al.  A questionnaire survey on the usage of low protein staple foods by people with phenylketonuria in Scotland. , 2014, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[18]  C. Zabala,et al.  Modelo de atención de la fenilcetonuria (PKU) en Uruguay , 2014 .

[19]  John J. Mitchell,et al.  Phenylalanine hydroxylase deficiency: diagnosis and management guideline , 2013, Genetics in Medicine.

[20]  J. Guest,et al.  Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet. , 2013, Journal of intellectual disability research : JIDR.

[21]  S. A. Banta-Wright,et al.  Breast-feeding success among infants with phenylketonuria. , 2012, Journal of pediatric nursing.

[22]  M. Baumgartner,et al.  Positive effect of a simplified diet on blood phenylalanine control in different phenylketonuria variants, characterized by newborn BH4 loading test and PAH analysis. , 2012, Molecular genetics and metabolism.

[23]  P. Burgard,et al.  The reality of dietary compliance in the management of phenylketonuria , 2010, Journal of Inherited Metabolic Disease.

[24]  S. Waisbren,et al.  Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. , 2007, Molecular genetics and metabolism.

[25]  Marcos B. Aguiar,et al.  Breastfeeding in the treatment of children with phenylketonuria. , 2007, Jornal de pediatria.

[26]  R. Koch,et al.  Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. , 2001, The American journal of clinical nutrition.

[27]  S. Murphy FOOD COMPOSITION DATA , 2013 .

[28]  María Laura Pardo,et al.  Modelo de atención de pacientes con fenilcetonuria (PKU) en Argentina , 2012 .

[29]  P. Acosta Recommendations for protein and energy intakes by patients with phenylketonuria , 2009, European Journal of Pediatrics.